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Objective: Prolonged air leak is reported in up to 50% of patients after lung volume
reduction surgery. The effect of an autologous fibrin sealant on the intensity and
duration of air leak and on the time to chest drain removal after lung volume reduction
surgery was investigated in a randomized prospective clinical trial.
Methods: Twenty-five patients underwent bilateral thoracoscopic lung volume reduc-
tion surgery. In each patient, an autologous fibrin sealant was applied along the staple
lines on one side, whereas no additional measure was taken on the other side. Ran-
domization of treatment was performed at the end of the resection on the first side.
Air leak was assessed semiquantitatively by use of a severity score (05 no leak; 45
continuous severe leak) by two investigators blinded to the treatment.
Result: Mean value of the total severity scores for the first 48 hours postoperative was
significantly lower in the treated group (4.7 6 7.7) than in the control group (16.0 6
10.1) (P , .001), independently of the length of the resection. Prolonged air leak and
mean duration of drainagewere also significantly reduced after application of the sealant
(4.5% and 2.86 1.9 days versus 31.8% and 5.96 2.9 days) (P5 .03 and P, .001).
Conclusions: Autologous fibrin sealant for reinforcement of the staple lines after lung
volume reduction surgery significantly reduces prolonged air leak and duration of
chest tube drainage.
P
rolonged air leak, defined as air leak lasting more than 7 to 10 days after ana-
tomic pulmonary resection, is often associated with pain owing to the chest
tubes and immobilization and is a major limiting factor for discharge from
the hospital.1-4 Various techniques of minimizing this complication have been tried
with mixed results, but the overall incidence of air leaks remains higher than 60%
in the early postoperative period.5 However, with the exception of very large air leaks
or association with a significant residual postresection space, most air leaks are benign
and resolve within a few days with appropriate drain management. Prolonged air leaks
occur in more than 15% of patients.6
Several prospective studies have demonstrated that lung volume reduction surgery
(LVRS) reduces dyspnea and improves lung function and quality of life in selected
patients with severe pulmonary emphysema.7-12 It has been shown that severe emphy-
sema is one of the most important risk factors for prolonged air leak.6 This increases
the risk for infections in patients undergoing LVRS. Inasmuch as prolonged air leak
may affect nearly half of the patients after LVRS in some series,6,13 such patients are
an ideal subgroup in which to evaluate new techniques to avoid or to reduce the
occurrence of this type of complication.
A variety of biologic and synthetic materials including fibrin sealants, collagen
fleece, and synthetic glues are commercially available to reinforce parenchymal staple
lines in an effort to decrease occurrence of postoperative air leak after pulmonary re-
section.1-5,14-18 The use of fibrin sealant in cardiothoracic surgery was pioneered in the
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mid-1970s. Today, fibrin sealant is used primarily as a hemo-
static and adhesive agent and as a sealant of pulmonary air
leaks.
The aim of this prospective randomized monocenter study
was to evaluate the effect of reinforcing the stapler lines with
an autologous fibrin sealant in a series of patients undergoing
LVRS, regarding incidence of prolonged air leak and dura-
tion of chest tube drainage.
Patients and Methods
Twenty-five patients with severe emphysema, including 7 men and
18 women with a mean age of 62 years (range 41–82 years), under-
went bilateral LVRS by video-assisted thoracoscopy between June
2005 and October 2006. Inclusion and exclusion criteria for this
procedure were the same as previously published.9 All patients
included in the study had severe airflow obstruction with a mean
forced expiratory volume in 1 second (FEV1) of 0.74 6 0.08 L
(27% 6 6.14% predicted), a mean total lung capacity of 7.66 6
1.14 L (137% 6 18.31% predicted), a mean residual volume of
5.146 1.06 L (244%6 56.63% predicted), and a severe hyperinfla-
tion with a mean residual volume/total lung capacity ratio of 0.686
0.1. Emphysema was scored on preoperative chest computed
tomography as homogeneous, intermediately heterogeneous, or
markedly heterogeneous according to a previously validated classi-
fication.9 The study was approved by the Human Investigation
Committee of our institution. Patients were invited to participate af-
ter explanation of the purpose and potential risks and benefits and
were required to sign informed consent. Inasmuch as only patients
who agreed to participate were included, it was not a consecutive
series of patients.
LVRS was performed bilaterally by video-assisted thoracoscopy
as previously described, using 60-mm and 45-mm stapler devices.9
The most damaged zones of lung parenchyma were identified on
computed tomography and perfusion scintigraphy and were resected
with endoscopic staplers. In patients with homogeneous emphy-
sema, the resection was performed mostly in the upper lobes. A cu-
mulative lung volume of approximately 30% on each side was
resected. All procedures were performed by the same surgeon
who has a large experience with LVRS. All patients had intraoper-
ative and postoperative thoracic epidural analgesia. After removal of
the catheter, a combination of paracetamol (Dafalgan) und metami-
zol (Novalgin) was generally considered for basic analgesia.
TheVivostat (Vivostat A/S,Alleroed,Denmark) system is a com-
mercially available medical device for the preparation of an autolo-
gous fibrin sealant from 120 mL of the patient’s blood in the
operating room.19 The system is fully automated andmicroprocessor
controlled and is made up of three components: an automated pro-
cessor unit, an automated applicator unit, and a disposable, single-
patient-use unit, which includes a preparation set and a Spraypen
applicator for thoracoscopic use. Time required to prepare autologous844 The Journal of Thoracic and Cardiovascular Surgery c Octfibrin sealant with this system is 20 minutes and the fibrin solution
may be kept at room temperature for up to 8 hours before application
without a loss of sealant effectiveness. The device provides a fine
aerosolized mist spray of fibrin sealant under pressure. The sealant
polymerizes on contact and sets over several minutes.19-21 We
did not receive any financial support from Vivostat A/S.
Design
At the end of the LVRS on the first side, this side was ran-
domly assigned in the operating room to the control or the
treatment group (Vivostat group) by opening a sealed enve-
lope. Hence, in each patient, there was always a treated and
a control side. In patients in whom the first operated side
was assigned to the control group, autologous fibrin sealant
was applied after LVRS on the contralateral side (treated
side). In patients in whom Vivostat was applied on the first
side, the contralateral side remained without additional treat-
ment (control side). On the treated sides, fibrin sealant was
sprayed with the lung deflated on the staple lines but also 1
cm at each side of the staple lines to prevent air leak after re-
inflation of the lung in these areas (Figure 1). At the end of the
operation, two 24F apical chest tubes were placed on each
side and were systematically set at 10 cm H2O suction.
Patients were extubated in the operating room.
The primary end points of the study were incidence and in-
tensity of air leaks after LVRS. The method used to determine
air leakwas semiquantitative, based on the relative intensity of
air bubbles appearing in the water reservoir of the drainage
system. Intensity of air leak was assessed by a severity score
ranging from 0 (no leak) to 4 (severe continuous air leak
with stream of bubbles or coalesced bubbles) (Table 1). This
score was defined by two independent observers blinded to
the treatment as soon as the patient had been transferred to
the intensive care unit, about 1.5 to 2 hours postoperatively,
as well as twice a day, each morning and each afternoon until
removal of the chest tubes. Each observer gave his own score
for each side. With this design, 2 scores were given for each
side at a predetermined time of assessment (Table 2). To assure
the reproducibility of this semiquantitative scoringmethod, the
two investigators had been familiarized with the severity score
a few weeks before the first patient was included.
Other end points were the severity scores for the first post-
operative 48 hours, the incidence of prolonged air leaks, and
the duration of chest tube drainage on each side. Since total
severity scores for the first postoperative 48 hours were
obtained as a sum of 8 severity scores (4 scores by each ob-
server) with possible values 0, 1, 2, 3, and 4, the total severity
scores took their values between 0 and 32 (Table 3). This has
been made to summarize the information and to get a better
statistical scale (which can be treated as a continuous end
point). Air leak duration was calculated as the interval from
the day of LVRS to the day of clinically determined cessation
of air leak. The criteria considered to remove the chest tubes
were only based on the intensity of air leak, assessed by theober 2008
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coscopic use. Polymerized fibrin sealant after
application on the staple lines.severity score of the two independent observers, and not on
the volume of pleural fluid. In our experience, the volume
drained after thoracoscopic LVRS is not relevant (some mil-
liliters per day) and is always smaller than the 100 or 150 mL
per day that is generally considered as a criterion to remove
a chest tube. This is a reason that patients with emphysema
are an ideal subgroup to evaluate duration of chest tube drain-
age owing to air leak, in comparison with patients who un-
dergo lobectomy. The volume of pleural fluid was not
assessed in this study.
Criteria for removal of the chest tubes were a score of 0 or
1 for the first chest tube with an expanded lung on chest x-ray
film. The last chest tube drain was removed as soon as no air
leak (score 0) was observed on the examined side. Postoper-
ative morbidity and mortality were recorded in all patients.
Statistical analysis was carried out using the software Sta-
tistical Package for the Social Sciences (SPSS, Inc, Chicago,
Ill). The sample size was calculated to get 80% power for the
primary end point (drainage duration) and increased by a few
units to account for the patients who are inevitably lost to fol-
low-up. The Vivostat group and the control group were com-
pared by a Wilcoxon signed rank test for the continuous end
points (length of resection, total of severity scores, duration
of drainage) and a McNemar test for the binary end point
(air leak). For drainage duration and air leak, only the 22 pa-
tients who could be observed until the end of the study (who
TABLE 1. Semiquantitative severity score for assessment
of the intensity of air leak after LVRS
Score Air leak
0 No air leak
1 Countable air bubbles only when coughing
2 Stream of babbles only when coughing
3 Continuous leak with countable air bubbles
4 Continuous air leak with stream of bubbles
LVRS, Lung volume reduction surgery.The Journal of Thorwere still alive and who did not require reintubation) have
been included. For total severity scores, only the patient
who died after 24 hours was not included.
Results
Pneumonia developed 4 and 7 days after surgery on the non-
treated side in 2 of the 25 patients enrolled in the study. The
two chest tube drains on the Vivostat side had already been
removed. The patients required reintubation and were ex-
cluded from further analysis for the end points air leak and
duration of drainage to rule out influence of ventilation on in-
tensity and duration of air leak in these patients. After reintu-
bation, no pneumothorax was observed on the treated side. A
third patient was completely excluded from further analysis.
This patient was a 77-year-old woman who had acute respi-
ratory failure and died in the intensive care unit the day after
LVRS. Pulmonary embolism was suspected.
The volume of fibrin sealant obtained from the patients’
blood was very reproducible, with a mean value of 4.8 mL
(ranging from 4.6 to 5 mL). Vivostat was used on the first op-
erated side in 10 patients and on the second side in 12 patients.
Length of resection was very comparable and not significantly
different in the two groups, with 21.66 7.3 cm in the treated
group versus 21.7 6 6.3 cm in the control group (P 5 .93).
LVRS was performed in the upper lobe, in the lower lobe,
TABLE 2. Incidence of the different severity scores given
by the two observers at 2 hours after LVRS according to
the treatment in the 22 patients who were considered for
analysis of air leak (2 scores for each patient)
Score
0 1 2 3 4
Vivostat group 25 10 0 5 4
Control group 6 13 6 7 12
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and in 7, 4, and 11 control sides, which was comparable.
There was no difference in the mean time spent during the
procedure on the first and on the second sides (326 9 minutes
vs 34 6 11 minutes) and there was no difference in the oper-
ation time between treated and control sides.
At the first observation time 2 hours postoperatively, sever-
ity score 0, 1, 2, 3, or 4was found 25, 10, 0, 5, and 4 times in the
Vivostat group and 6, 13, 6, 7, and 12 times in the control group
(P , .02). Total severity score was significantly lower in the
Vivostat group (4.7 6 7.7) than in the control group (16.0 6
10.1) (P , .001). No correlation with the localization of the
resection and with the length of the staple lines was observed.
The two observers were in very good agreement, the weighted
kappa calculated on the basis of all ratings made by each
observer 48 hours postoperative being 0.89.
Prolonged air leak (.7 days) was observed in 8 (18.2%)
of 44 operated sides. However, prolonged air leak was found
in only 1 (4.5%) of 22 treated sides as compared with 7
(31.8%) of 22 control sides (P5 .031). Among the 7 patients
with prolonged air leak on a control side, reoperation was
necessary in 2 patients after 11 and 12 days.
TABLE 3. Total of severity scores for the first 48
postoperative hours for both investigators (4 times of
assessment giving 8 observations and total scores between
0 and 32) and duration of the chest tube drainage (in hours)
Severity scores Duration of drainage
Patient Vivostat side Control side Vivostat side Control side
1 0 4 45 117
2 0 29 45 261*
3 2 1 117 69
4 26 31 117 213*
5 5 24 45 93
6 16 23 45 213*
7 0 18 117 213*
8 5 2 69 69
9 0 28 45 141
10 12 31 117 213*
11 0 14 45 141
12 0 15 45 93
13 3 2 45 45
14 1 10 45 213*
15 3 12 45 93
16 0 7 45 69
17 0 24 45 117
18 26 26 237* 285*
19 0 0 45 45
20 2 17 45 165
21 1 8 45 93
22 0 11 45 141
23 3 18
24 7 24
*Prolonged air leak (.7 days).846 The Journal of Thoracic and Cardiovascular Surgery c OcMean duration of chest tube drainage was also signifi-
cantly reduced after application of the sealant (2.83 6 1.96
days vs 5.886 2.96 days; P, .001). Again, the localization
of the resection as well as the length of resection had no in-
fluence on the duration of drainage. It was also impossible
to find a difference in the duration of air leak between the first
and the second operated sides, ruling out an influence of the
pressure applied on the first operated side during operation
on the second side. Mean duration of air leak for the first
operated sides was 4.9 6 3.1 days in comparison with 4.1
6 2.7 days for the second side. This observation was also
noted if the comparison was only performed in the subgroup
Vivostat sides (Vivostat on the first side vs Vivostat on the
second side) and in the subgroup nontreated sides (no treat-
ment on the first side vs no treatment on the second side).
After removal of the drains and before discharge from the
hospital, chest radiography was routinely performed. The
lungs were completely expanded in each patient. Clinical
and radiologic studies at 3, 6, 9, 12, 15, 18, and 24 months
were performed postoperatively at our center. After a mean
follow-up time of 17.3 months, no recurrent pneumothorax
was documented.
With the design of this study, it was not possible to com-
pare postoperative analgesics requirement and duration of
hospitalization, since a treated side and a control side were
randomly assigned in each patient. The mean duration of hos-
pitalization was 10.5 6 3.2 days.
No adverse effects owing to the sealant were recorded dur-
ing the study.
In-hospital mortality rate was 12% (3/25). Two patients
died of pulmonary embolism 1 day after surgery and of pneu-
monia at 10 days, 3 days after reintubation. The third patient
died 13 days after LVRS of intracerebral bleeding.
Discussion
This prospective randomized study demonstrates that the use
of the autologous fibrin sealant Vivostat for reinforcement of
the staple lines after LVRS significantly reduces the inci-
dence and the intensity of postoperative air leak as well as
the incidence of prolonged air leak and duration of chest
tube drainage. This is the first prospective randomized study
evaluating the efficacy of autologous fibrin sealant in patients
with severe emphysema, who represent an ideal subgroup for
such an analysis, having an increased risk for air leak after
LVRS in comparison with patients undergoing anatomic
pulmonary resection. Thus, the prevention or elimination of
air leaks after LVRS is an important goal, as it may facilitate
early removal of chest tubes, thereby reducing postoperative
pain and facilitating postoperative recovery by avoiding
pulmonary complications. This is important inasmuch as
pneumonia occurs in up to 15% of patients after LVRS
despite prophylactic antibiotics.13
Several methods have already been described to reduce
the incidence of air leak after pulmonary resection. Previoustober 2008
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have given inconsistent results with regard to air leakage and
the duration of chest tube drainage. Wong and Goldstraw,15
in a randomized trial of 66 patients with alveolar air leaks
after pulmonary surgery, identified a nonsignificant but
shorter duration of chest tube drainage and hospitalization.
Fleischer and associates14 were also unable to identify a sig-
nificant effect of fibrin sealant in reducing the duration of
chest tube drainage and hospitalization and in the duration
of air leakage. Gagarine and colleagues,4 in a retrospective
study of 360 patients, did identify a significant reduction of
drainage in patients who received fibrin sealant, but the inci-
dence of prolonged air leak was comparable. A possible ex-
planation for these heterogeneous results is that most of air
leaks after anatomic pulmonary resection resolve spontane-
ously in a few days. The study by Fabian, Federico, and
Ponn5 was the first randomized trial showing a decrease in
the duration of chest tube drainage (3.5 days vs 5 days) after
lung resection for malignant and benign diseases. However,
the fibrin sealant used was not autologous. Conventional fi-
brin sealants use components prepared from pooled human
plasma and sometimes animal-derived components. The
Vivostat system overcomes the potential infective and anti-
genic risks associated with the use of other available fibrin
sealants containing products derived from pooled human fi-
brinogen or using exogenous thrombin, especially of bovine
origin.21 A recent prospective randomized trial by Anegg and
coworkers22 showed that the use of fleece-bound sealing after
pulmonary resection resulted in a reduction in air leakage
compared with standard techniques. This reduction in air
leakage resulted in a significant reduction in both the time
to chest drain removal and the length of hospitalization.
The major disadvantage of this method is the great difficulty
in using fleece-bound sealing thoracoscopically.
In patients with severe emphysema undergoing LVRS,
buttressing of staple lines with bovine pericardial strips or
polytetrafluoroethylene sleeves achieved popularity in deal-
ing with the rarefied emphysematous lung tissue of patients
with severe emphysema and has also been applied to routine
lobectomy. However, its effectiveness remains unclear.
Hazelrigg and associates23 found a 2- to 3-day reduction in
length of hospital stay when buttressing. In a randomized,
three-center trial, Stammberger and coworkers24 reported
a statistically significant reduction in air leak duration after
bilateral, buttressed, thoracoscopic LVRS, but no reduction
in length of stay. A disadvantage of this technique consists
in the extensive inflammatory reaction with formation of
dense adhesions associated with the use of bovine pericar-
dium, which makes lung transplantation after LVRS particu-
larly challenging when indicated.
In the National Emphysema Treatment Trial, more than
95% of the surgical patients underwent staple-line buttress-
ing, the majority with pericardium and polytetrafluorethy-
lene. Within 30 days of LVRS, 90% of patients had an airThe Journal of Tholeak.8 The authors concluded that the surgical approach, but-
tressing, and intraoperative adjunctive procedures were not
associated with fewer or less prolonged air leaks. However,
fibrin sealant was only used in 32 patients (5.8%) in this mul-
ticentric study, which does not allow the drawing of any
strong conclusion on its application. Interestingly, the occur-
rence of air leak in the National Emphysema Treatment Trial
was more common and its duration prolonged in patients
with lower diffusing capacity, upper lobe disease, and impor-
tant pleural adhesions. Duration was also protracted in pa-
tients using inhaled steroids and those with a lower FEV1.
8
Cerfolio and coworkers25 also observed that persistent air
leak mostly developed in patients with an FEV1 of less
than 79% predicted. The authors concluded that the occur-
rence and the duration of air leaks were associated with
patients’ characteristics and disease severity and not with
a specific surgical technique. In our study, patients’ charac-
teristics could not explain the difference between the two
groups, since in each patient a treated side and a control
side were assigned. Furthermore, all the operations were per-
formed by the same surgeon, using the same technique of
resection. We found that the localization of resection and
length of the staple lines were correlated neither with the in-
cidence and the intensity of air leak nor with the duration of
chest tube drainage. The only difference between the two
sides was the application or not of autologous fibrin sealant.
The autologous fibrin sealant Vivostat was first used in
cardiac surgery and has already been applied at the anastomo-
ses, the mammary artery pedicle, the mediastinum, and the
sternal marrow for hemostasis.19,20 It has also been used in
lung surgery and has been shown to reduce postoperative
air leakage and drainage volumes after lobectomy.18 How-
ever, no difference was observed in the duration of drainage
and in the length of hospital stay. Again, this might underline
that most air leaks after anatomic pulmonary resection are
generally innocuous and can be managed conservatively by
chest tube drainage.
Advantages of theVivostat system aremultiple. It is a fully
automated device and autologous fibrin sealant can be pre-
pared with a stable concentration and volume by a nurse or
perfusionist. Thoracoscopic application is easy and safe.
The Spraypen system allows the surgeon to spray the solution
evenly over the target tissue in a controlled fashion. Applica-
tion is controlled by a foot pedal and can be stopped and
restarted without the problem of the fibrin congealing. The
sealant polymerizes immediately on application and cross-
links over several minutes. Fibrin sealant Vivostat sealant
is flexible and compliant to accommodate the volume
changes of the lung, resulting in a uniform surface load and
minimizing the potential for secondary tearing of tissue at
the application site.21
The incidence of prolonged air leak, defined as an air leak
that lasts at least 7 days after the procedure, was 31.8% in the
control group. This compares favorably with the 40% to 60%racic and Cardiovascular Surgery c Volume 136, Number 4 847
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dence was 4.5%, which was comparable with the data of
the most important reports using fibrin sealants but was better
than with other techniques (24% after fleece-bound sealing).22
Additionally, this incidence could have been expected to be
higher, inasmuch as prolonged air leak is observed more fre-
quently in patients with severe emphysema.13 Our data dem-
onstrate that autologous fibrin sealant considerably reduces
the incidence of air leak, but does not eliminate it. This can
be easily explained in patients with severe emphysema, in
whom a minimal trauma of the fragile lung parenchyma, par-
ticularly during reinflation, suffices to produce a pleural
fistula. In a study of hospital stay after thoracic operations,
prolonged air leak was identified as the most common cause
of the delay in discharge.4,26 In a previous report estimating
hospital costs attributable to prolonged air leak in pulmonary
lobectomy, Varela and colleagues26 found that prolonged air
leak calculated costs were over 13,000 euros per year in his
institution. However, the techniques used to reduce air leaks
are also often expensive, for example, up to 350 euros. The
cost of the fibrin sealant prepared with the Vivostat system
is about 200 euros, which compares favorably with the other
sealing techniques. Moreover, the application system with the
Spraypen allows delivery of the fibrin to larger areas than with
many other techniques. In our opinion, reinforcement of the
staple lines after lung resection is not routinely required.
The main reason is that most of the leaks will resolve sponta-
neously if the lung can re-expand.
Mean duration of chest tube drainage in the Vivostat
group was 2.8 days, which is shorter than in most prospective
randomized trials evaluating the effect of fibrin sealants (5 to
6 days).14,15 Only the study by Fabian and associates5
revealed a value of 3.5 days, but after anatomic pulmonary
resection.
The mortality rate of 12% found in this study is high and
does not reflect the mortality rate of our published series of
194 patients who underwent LVRS at our institution, which
is 2.6%.27 As already mentioned, the inclusion criteria for
LVRS were the same as in previously published reports
from our center. This high rate is probably coincidental, ow-
ing to the small number of patients included in the study.
Our study has some drawbacks. First, the number of pa-
tients included was relatively small. This is partially due to
the fact that although our institution is one of the leading ref-
erence centers for LVRS, this procedure is only performed in
highly selected patients. On the other hand, this study pres-
ents the possible advantages of a monocenter study, inas-
much as the surgeon and the technique used for resection,
as well as perioperative management, were identical in all
patients. Additionally, the design assigning a treated and
a control side in each patient allowed increasing the number
of observations. Second, the intensity of air leak was not ex-
actly quantified. However, precise quantification of air leak is
still not the standard of care in most centers and has not been848 The Journal of Thoracic and Cardiovascular Surgery c Octdemonstrated to change and to influence clinical decision-
making regarding removal of the chest tubes. Third, random-
ization was not performed for each side but only for the first
side after LVRS had been performed, the second side being
automatically assigned to the other group. This design has
been chosen for the following reason: the preparation of
autologous fibrin sealant needs about 20 minutes. A random-
ization for each side might have provoked delay in the oper-
ating theater if both sides had been assigned to the treatment
group. Our study design allowed having more observations
(2 in each patient), ruling out the influence of patients’ char-
acteristics and of localization of emphysema.
In conclusion, this study demonstrated that the use of
autologous fibrin sealant Vivostat significantly reduces the
incidence of prolonged air leak and duration of chest tube
drainage in patients undergoing LVRS for severe emphy-
sema. Reinforcement of the staple lines with this technique
is surely a safe and efficient way, in addition to a careful sur-
gical technique by an experienced surgeon and adequate
postoperative care, to prevent and minimize potential compli-
cations in these patients, which is key to successful LVRS.
As a consequence, the autologous fibrin sealant Vivostat
might be systematically used in this highly selected subgroup
of patients.
We thank Daniel Demierre for his contribution to the realization
of this study.
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